Loading clinical trials...
Loading clinical trials...
A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study of an Anti-PD-L1 Monoclonal Antibody CS1001 in Subjects with Advanced Solid Tumors
Conditions
Interventions
CS1001
Locations
1
United States
NEXT Oncology
San Antonio, Texas, United States
Start Date
December 4, 2018
Primary Completion Date
October 31, 2020
Completion Date
July 21, 2021
Last Updated
September 19, 2024
NCT06898450
NCT05719558
NCT07029399
NCT04826341
NCT06819735
NCT06760819
Lead Sponsor
CStone Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions